article thumbnail

Newly Approved T1D Therapy Lantidra Could Eliminate Need for Insulin Injections

XTalks

Making for another landmark cell and gene therapy approval this month, the US Food and Drug Administration (FDA) has signed off on CellTrans’ Lantidra (donislecel), the first cell therapy for type 1 diabetes. Lantidra is thought to increase insulin secretion through the infusion of allogeneic insulin-producing islet beta cells.

Insulin 98
article thumbnail

Vertex signs agreement to acquire ViaCyte for $320m

Pharmaceutical Technology

VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy of Vertex for T1D. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Through the acquisition, Vertex plans to advance its potentially curative VX-880 programmes in T1D.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Pharmalittle: Vertex exec says prices for gene therapies are ‘in the ballpark’; insulin access in poor countries remains spotty

STAT News

Bluebird also recently said it would charge $3 million for Skysona, the gene therapy it just launched for a rare brain-wasting disease.  Even a drug-price watchdog, the Institute for Clinical and Economic Review, deemed the $2.8 Continue to STAT+ to read the full story…

article thumbnail

Vertex signs licence deal with CRISPR Therapeutics for diabetes therapies

Pharmaceutical Technology

“Having successfully demonstrated clinical proof of concept in T1D in our VX-880 programme, we are excited to deepen our relationship with CRISPR Therapeutics with this agreement, which will allow us to further accelerate our goal of generating fully differentiated, insulin-producing hypoimmune islet cells for T1D.”

article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

For cell and gene therapy applications, you need a variety of speciality enzymes of the highest purity, specificity, and consistency. In 2021, Novo Nordisk Pharmatech, a leading pharmaceutical-grade insulin and Quats product supplier announced plans to enter the enzyme market. Developing best-in-class speciality enzymes.

Drugs 295
article thumbnail

Controlling insulin production with a smartwatch

Scienmag

Credit: ETH Zurich Many modern fitness trackers and smartwatches feature integrated LEDs. The green light emitted, whether continuous or pulsed, penetrates the skin and can be used to measure the wearer’s heart rate during physical activity or while at rest. These watches have become extremely popular.

Insulin 95
article thumbnail

Hybrid closed-loop insulin therapy improves glycemic control

Scienmag

publishers New Rochelle, NY, January 26, 2021–Hybrid closed-loop insulin therapy improved glycemic control in adolescents and young adults with type 1 diabetes. Credit: Mary Ann Liebert, Inc.,

Insulin 55